BioProcess International E-Book: Robust Platform Technologies Can Streamline Next-Generation T-Cell Engager Development

In this eBook, Bioprocess International’s editor-in-chief shows how antibody engineering is positioned at the forefront of precision medicine. Abzena’s Scientific Leader, Petra Dieterich, VP of Research & Innovation, Rob Holgate & Sr. Manager of Protein Engineering, Thomas Cornell, provide a deep-dive example of platform engineering for bispecific t-cell engagers.

E-book overview

The antibody engineering field is experiencing rapid transformation driven by computational advances and sophisticated molecular architectures. Machine learning and artificial intelligence platforms are dramatically accelerating antibody design, potentially reducing timelines from years to months. Industry and academia are working together to leverage digital models for developability predictions and affinity optimization. Multispecific antibodies and fragment engineering offer new modes of action and improved tissue penetration. Developers can prioritize safety and efficacy while integrating manufacturability assessment early in development.

Click here to download the e-book

For over 20 years Abzena has been providing antibody design and protein engineering services and solutions to accelerate biopharmaceutical development. Working together with our customers, we have overcome a wide range of drug design challenges. From antibody discovery through to cell line development we can engineer, express, purify and characterize your molecules. Utilizing experience from successfully delivering many hundreds of projects, our experts work relentlessly to meet your needs, enhance efficiency, and mitigate risk. For more information about Abzena’s extensive antibody engineering expertise, download our info sheet.